Lung Cancers Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04027946LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT03693014A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsTreatment
NCT03526887Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLCTreatment